"South Africa Pharmaceuticals & Healthcare Report Q1 2016" is now available at Fast Market Research

A compulsory licence for Aluvia in South Africa remains unlikely given that country's reluctance to resort to such measures. The request puts pressure on AbbVie to address supply issues, but more importantly reminds South Africa's g overnment that expectations over the stalled efforts to amend the country's patent laws remain high. The g overnment has made assurances that movement will be seen in Q116; failure to do so will risk a political storm.

Headline Expenditure Projections

Pharmaceuticals: ZAR39.79bn (USD3.67bn) in 2014 to ZAR43.41bn (USD3.44bn) in 2015; +9.1% in local currency terms and -6.2% in US dollar terms. Forecast in US dollar terms revised slightly downwards from last quarter.
Healthcare: ZAR325.2bn (USD29.98bn) in 2014 to ZAR351.06bn (USD27.82bn) in 2015; +8.0% in local currency terms and -7.2% in US dollar terms. Forecast in US dollar terms revised slightly downwards from last quarter.

Full Report Details at
- http://www.fastmr.com/prod/1109985_south_africa_pharmaceuticals.aspx?afid=301

Risk/Reward Index

South Africa has strong longer-term commercial potential because of its sizeable population and economic development. However, the impact of currency depreciation and a worsening economic outlook have hurt its short-term growth prospects. In Q116, South Africa dropped from seventh to ninth position in the matrix compared to previous quarter, with a score of 49.0 out of 100.

The South Africa Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's South Africa Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the South Africa pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for South Africa, to test other views - a key input for successful budgeting and strategic business planning in the South African pharmaceutical and healthcare market.
* Target business opportunities and risks in the South African pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in South Africa.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View



About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q1 2016
- South Africa Pharmaceuticals & Healthcare Report Q4 2015
- Ghana Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Japan Pharmaceuticals & Healthcare Report Q1 2016